Evince Management

Paulo Rangel

Paulo Rangel

President & CEO, Co-founder

Mr. Rangel is responsible for Evince’s strategy and external activities. Before Evince, Mr. Rangel was a Partner at ProPharma Partners International, an international consulting group. He concentrated on working with biopharmaceutical and medical device companies on worldwide in- and out- licensing, valuations, business plans and market research. Before ProPharma, Mr. Rangel was Head of Global Business Development at Besins Healthcare, a global pharmaceutical company with products targeted at women’s and men’s health. Mr. Rangel was a Founder of, and key executive in, two medical device start-ups, Lasercure Sciences and 5i Sciences (now Sommetrics). In those positions, he completed the financing, clinical studies and collaborations, and was responsible for all intellectual property. Mr. Rangel has been involved with a number of other biotechnology companies and worked at companies such as Amgen and Hybritech/Lilly early in his career. Mr. Rangel received a B.A. in chemistry/biochemistry from the University of California at San Diego and an M.B.A. from Duke University.

Jim Appleman

James Appleman Ph.D.

SVP Research and Development, Chief Scientific Officer

Dr. Appleman brings nearly 30 years of experience in building successful drug discovery organizations in small companies. He has particular expertise in the implementation and application of novel information technologies to drug discovery and development. Dr. Appleman is a co-founder of eFFECTOR Therapeutics ($45M original Series A funding) where he established both the bioinformatics infrastructure and technology base to support eFFECTOR’s unique programs targeting dysregulated mRNA translation. Previously he served as Senior Vice President, Research and Chief Scientific Officer at Anadys Pharmaceuticals, Inc. where he played pivotal roles in the invention, characterization and clinical development of the Company's drug candidates Setrobuvir and ANA773 and in the acquisition of Anadys by Roche for $230M (256% premium to market cap). ANA773 is a novel TLR7 agonist intended for the treatment of hepatic viral diseases and cancer. Dr. Appleman personally led the ANA773 project team from selection of medchem starting points through preclinical development and IND filing. Prior to joining Anadys, Dr. Appleman held positions at Gensia, Inc. and it’s subsidiary Metabasis Therapeutics and was a faculty member at St. Jude Children's Research Hospital. He received a Ph.D. in Biochemistry from Oklahoma State University and completed his postdoctoral training at Dartmouth Medical School.

Aiden Aceves

Aiden Aceves

Chief Technology Officer

Mr. Aceves received his formal training at the University of California, Riverside, where he conducted research in toxicology, ecological modeling and cheminformatics. His primary expertise falls in the areas of statistical analysis and machine learning – skills refined and proven over the course of the three years Mr. Aceves has worked to bring AVO from idea to product. As the lead developer of the AVO platform, Mr. Aceves has experience in employing and developing advances in high performance computing, machine learning models, and robust packages for cheminformatics processing. Drawing on a strong quantitative background, Mr. Aceves recent work has been in the areas of deep-learning, heuristic functions, and cloud-backed scalable systems.